Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDO2 | P48775 | 13/20 | 0.66 |
| ▸ | IDO1 | P14902 | 12/20 | 0.66 |
| ▸ | NOS1 | P29475 | 3/20 | 0.53 |
| ▸ | AXL | P30530 | 1/20 | 0.53 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.49 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.48 |
| ▸ | METAP2 | P50579 | 2/20 | 0.48 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1318814 | 0.83 | TDO2 (0.61) | TDO2IDO1NOS1AXLDYRK1A | |
| SCHEMBL29397622 | 0.83 | TDO2 (0.61) | TDO2IDO1NOS1AXLDYRK1A | |
| SCHEMBL20176611 | 0.79 | NOS1 (0.50) | TDO2IDO1NOS1AXLPTPN6 | |
| SCHEMBL31642655 | 0.79 | NOS1 (0.50) | TDO2IDO1NOS1AXLPTPN6 | |
| SCHEMBL29793852 | 0.79 | METAP2 (0.53) | TDO2IDO1NOS1AXLPTPN6 | |
| SCHEMBL2007139 | 0.79 | IDO1 (0.59) | TDO2IDO1NOS1AXLPTPN6 | |
| SCHEMBL2003535 | 0.79 | METAP2 (0.53) | TDO2IDO1NOS1AXLPTPN6 | |
| SCHEMBL1415060 | 0.79 | NOS1 (0.50) | TDO2IDO1NOS1AXLPTPN6 | |
| SCHEMBL31217417 | 0.79 | IDO1 (0.56) | TDO2IDO1NOS1AXLPTPN6 | |
| SCHEMBL29793841 | 0.79 | IDO1 (0.59) | TDO2IDO1NOS1AXLPTPN6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9999616-B2 | — | — | 2018-06-19 | — | — | US | disclosed |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | RVX THERAPEUTICS INC. (CA) | 2017-08-03 | — | — | US | disclosed |
| US-9662311-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-9662311-B2 | Substituted bicyclic compounds as bromodomain inhibitors | ZENITH EPIGENETICS LTD. (CA) | 2017-05-30 | — | — | US | disclosed |
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-30 | — | — | US | disclosed |
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | ZENITH EPIGENETICS CORP. (CA) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160184273-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | TDO2 3967/4885IDO1 1725/4885NOS1 4755/4885 |
| US-20170216257-A1 | NOVEL SUBSTITUTED BICYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS | BRD4, BRD3, BRD2 | TDO2 3967/4885IDO1 1725/4885NOS1 4755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.